Tempest Therapeutics, Inc.
TPSTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tempest Therapeutics, Inc. focuses on Biotechnology services and products. Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. At a $8.6M market cap, Tempest Therapeutics, Inc. ranks as a micro-cap company within healthcare. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Market Cap
$8.6M
Beta
-1.71
P/E (TTM)
—
P/E (Fwd)
-0.42
EPS (TTM)
$-3.93
EPS (Fwd)
$-1.21
ROE
-931.1%
ROA
-79.4%
Cash
$779,000
Total Debt
$7.6M
Free CF
-$15.5M
52W Change
-95.2%
Annual Financials
Cash vs Debt
Where TPST stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TPST finished 53.85% below its 150-day moving average ($1.30) and 62.73% below its 200-day moving average ($1.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TPST overbought or oversold?
At the October 20, 2026 close, TPST's RSI(14) was 11.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $779K in cash, though total debt stands at $7.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$15.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -931.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -1.71 suggests TPST is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TPST.